BridgeBio Pharma CFO covers taxes with 22,781 shares

BridgeBio Pharma, Inc. (BBIO) reported that President and CFO Thomas Trimarchi had 22,781 shares of common stock withheld on August 16, 2026 to satisfy tax obligations related to the vesting of 41,194 RSU-based shares.

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) reported that President and CFO Thomas Trimarchi had 22,781 shares of common stock withheld on August 16, 2026 to satisfy tax obligations related to the vesting of 41,194 RSU-based shares. After this tax-withholding disposition, he directly held 336,529 shares, which includes 116 shares acquired on August 14, 2026 through the company’s Employee Stock Purchase Plan.

Insider Trade Summary

Tax Withholding: 22,781 shares

Tax Withholding 1 txn

Insider Trimarchi Thomas

Role President and CFO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1, F2	22,781	$79.86	$1.82M

Holdings After Transaction: Common Stock — 336,529 shares (Direct)

Footnotes (2)

1. F1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 41,194 shares of Common Stock underlying the Reporting Person's RSUs.
2. F2. Includes 116 shares of the Issuer's Common Stock acquired by the Reporting Person on August 14, 2026 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.

Key Figures

Shares withheld for taxes: 22,781 shares Per-share value for withholding: $79.86 per share RSU shares vesting: 41,194 shares +2 more

5 metrics

Shares withheld for taxes 22,781 shares Common stock withheld on August 16, 2026 for tax obligation on RSU vesting

Per-share value for withholding $79.86 per share Value used for the 22,781 withheld common shares

RSU shares vesting 41,194 shares Common stock underlying RSUs that vested for the reporting person

Shares owned after transaction 336,529 shares Direct common stock holdings following the August 16, 2026 transaction

ESPP shares acquired 116 shares Common stock acquired August 14, 2026 under Employee Stock Purchase Plan

Key Terms

Restricted Stock Units, Employee Stock Purchase Plan, Rule 16b-3

3 terms

Restricted Stock Units financial

"vesting of 41,194 shares of Common Stock underlying the Reporting Person's RSUs"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Employee Stock Purchase Plan financial

"acquired by the Reporting Person on August 14, 2026 pursuant to the Issuer's Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Rule 16b-3 regulatory

"in a transaction exempt under Rule 16b-3"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BBIO’s President and CFO report on August 16, 2026?

BridgeBio Pharma (BBIO) President and CFO Thomas Trimarchi reported a tax-withholding disposition of 22,781 shares of common stock. The shares were withheld to cover taxes from the vesting of 41,194 RSU-related shares.

How many BBIO shares does Thomas Trimarchi hold after the reported Form 4 transaction?

After the August 16, 2026 transaction, Thomas Trimarchi directly holds 336,529 shares of BridgeBio Pharma common stock. This figure includes 116 shares acquired on August 14, 2026 under the company’s Employee Stock Purchase Plan.

Was the BBIO Form 4 transaction a market sale or tax withholding event?

The reported Form 4 event for BBIO was a tax-withholding disposition, not an open-market sale. 22,781 shares were withheld to satisfy Thomas Trimarchi’s tax obligations from vesting RSUs totaling 41,194 shares.

What RSU vesting activity triggered the BBIO insider tax withholding?

The tax withholding was triggered by the vesting of 41,194 shares of BridgeBio common stock underlying RSUs held by Thomas Trimarchi. To cover associated taxes, 22,781 shares of common stock were withheld instead of being sold on the market.

Did Thomas Trimarchi acquire any BBIO shares around the time of this Form 4 filing?

Yes. The post-transaction holdings include 116 shares of BBIO common stock that Thomas Trimarchi acquired on August 14, 2026 under the company’s Employee Stock Purchase Plan, in a transaction exempt under Rule 16b-3.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 06:03 PM Accepted by SEC EDGAR 08/18/2026 - 06:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trimarchi Thomas

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/16/2026		F		22,781(1)	D	$79.86	336,529(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 41,194 shares of Common Stock underlying the Reporting Person's RSUs.

2. Includes 116 shares of the Issuer's Common Stock acquired by the Reporting Person on August 14, 2026 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)